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Intratumoral Administration of Secondary Lymphoid Chemokine 
and Unmethylated Cytosine-phosphorothioate-guanine 
Oligodeoxynucleotide Synergistically Inhibits Tumor Growth  
in Vivo
Secondary lymphoid tissue chemokine (SLC), which is expressed in T cell zones of secondary 
lymphoid organs, including the spleen and lymph nodes, strongly recruits both T 
lymphocytes and mature dendritic cells. As appropriate interaction of tumor-specific T cells 
and mature dendritic cells, equipped with tumor antigens, is a prerequisite for effective T 
cell immunity against established tumors, we mobilized lymphocytes and dendritic cells to 
tumor sites by intratumoral injection of secondary lymphoid tissue chemokine-Fc (SLC-Fc) 
fusion protein using the B16F10 murine melanoma model. Activation of dendritic cells, 
another prerequisite for the effective activation of naïve tumor-specific T cells, was 
achieved by the addition of immunostimulatory cytosine-phosphorothioate-guanine 
oligodeoxynucleotide (CpG-ODN) into the tumor site. Intratumoral administration of SLC-
Fc or CpG-ODN revealed antitumor effects against B16F10 murine melanoma grown in the 
subcutaneous space. Co-treatment of SLC-Fc and CpG-ODN displayed synergistic effects in 
reducing the tumor size. The synergistic antitumor effect in co-treatment group was 
correlated with the synergistic/additive increase in the infiltration of CD4
+ T cells and 
CD11c
+ dendritic cells in the tumor mass compared to the single treatment groups. These 
results suggest that the combined use of chemokines and adjuvant molecules may be a 
possible strategy in clinical tumor immunotherapy. 
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INTRODUCTION 
The effective induction of antitumor immune responses is cru-
cial in tumor immunotherapy. The initiation of adaptive immu-
nity against a tumor depends heavily on tumor-specific T cell 
interactions and activation with antigen presenting cells (APCs) 
appropriately loaded with tumor antigens on their MHC mole-
cules (1). Dendritic cells (DCs) are the APCs for the initiation of 
an adaptive T cell immune response (2). Responding to appro-
priate activating signals, immature tissue DCs that take up tu-
mor antigens turn into activated DCs and migrate into draining 
lymph nodes (LNs), activating tumor-specific T cells. Interac-
tion of activated DCs and recirculating lymphocytes is facilitat-
ed within the T cell zones of LNs. Activated tumor-specific T 
cells in turn migrate from the LNs and move into the tumor site, 
attacking tumor cells (3). 
  Because most of the tumor-specific naïve T cells recirculate 
within the vascular system and the secondary lymphoid organ 
tumor antigens are confined in peripheral tissues, and because 
tissue-resident DCs are immature and thus tolerogenic, it is dif-
ficult for tumor-specific T cells to be fully activated. To create an 
environment in which naïve T cells and mature DCs meet, we 
propose to use a chemoattractant that can attract both of these 
cell components into the tumor site.
  Chemokines are a group of homologous, functionally diver-
gent proteins that mediate leukocyte migration and activation 
(4). Chemokines also function in maintaining immune homeo-
stasis and secondary lymphoid organ architecture (5). Second-
ary lymphoid tissue chemokine (SLC, CCL21), a cystein-cystein 
(C-C) chemokine expressed by high endothelial venules in the 
T cell zones of secondary lymphoid organs such as the spleen 
and LNs, strongly recruits both naïve and central memory T cells 
and mature DCs (6, 7). Receptors of SLC, C-C chemokine recep-
tor 7 (CCR7) and C-X-C chemokine receptor 3 (CXCR3), are spe-
cific G protein-coupled seven-transmembrane domain chemo-
kine receptors (4). CCR7 is expressed in naïve and central mem-
ory T cells and mature DCs. CXCR3 is expressed preferentially 
in Th1 cytokine-producing lymphocytes with memory pheno-
types (8, 9).
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ing unmethylated cytosine-phosphorothioate-guanine (CpG) 
motifs. Tokunaga et al. (10) was the first to report that DNA ex-
tracted from Mycobacterium bovis activated natural killer cells 
to produce interferon and to induce antitumor activity. This re-
search group also established that particular sequences with 
5´-CpG-3´ motif(s) are essential for these effects (10). Synthetic 
CpG-ODN was reported to have similar immunologic effects 
(11) by activating innate immunity through Toll-like receptor 9 
(12). CpG-ODN has less toxicity than other adjuvants, such as 
Freund’s adjuvant (13), and particular interest is focused on the 
induction and activation of Th1 cells and CD8
+ cytotoxic T lym-
phocytes through the activation and maturation of DCs (14, 15). 
  Melanoma is the main cause of death due to skin malignan-
cies. Although surgery can be curative for most patients with ear-
ly thin melanoma, 5-yr survival rates of patients with high-risk, 
thick melanoma are as low as 25% despite recent advances in 
melanoma therapy (16). B16F10 melanoma cells, which origi-
nated from C57BL/6 (B6) mice, produce tumor masses in syn-
geneic B6 mice when injected subcutaneously. Several tumor-
specific antigens characterized from melanoma cells are weakly 
immunogenic and do not raise an effective anti-melanoma im-
mune response in syngeneic B6 mice. 
  To produce an effective antitumor immune response directly 
inside the tumor, we set up an experimental melanoma model 
by subcutaneously injecting B16F10 melanoma cells into B6 
mice and applied SLC directly into the established tumor, which 
could recruit T lymphocytes and DCs (17). We used the SLC-Fc 
fusion protein to enhance in vivo molecular stability (18) and 
CpG-ODN as an adjuvant immune stimulator to produce the 
required DC activation during the initial interaction with tumor-
specific T cells. Combined chemokine and adjuvant therapy was 
highly efficient in inhibiting tumor growth, and this effect was 
dependent on T cells and activated DCs accumulating in the 
tumor sites. 
 
MATERIALS AND METHODS 
Cell lines
B16F10 mouse melanoma cells were obtained from the Ameri-
can Type Culture Collection (ATCC no. CRL-6475) and were cul-
tured in RPMI 1640 media supplemented with 10% heat-inacti-
vated fetal bovine serum and 1% antibiotics. NS0 cells were pur-
chased from the European Collection of Cell Cultures (ECACC 
no. 85110503) and cultured in conditions identical to the B16F10 
cells, except with 1% L-glutamine added to the media. 
Oligodeoxynucleotide
The oligonucleotide sequence containing the unmethylated CpG 
motifs (underlined; CpG-ODN: 5´-TCCATGACGTTCCTGAC-
GTT-3´) was synthesized at GenoTech (Daejeon, Korea). 
Secondary lymphoid tissue chemokine-Fc fusion protein 
production
Total RNA was isolated from the spleen using Trizol (Invitrogen, 
Carlsbad, CA, USA). cDNA was generated from 1 µg total RNA 
by Superscript II (Invitrogen). PCR of the murine SLC gene was 
performed using the following primers: 5´-CCG CTC GAG GCC 
ACC ATG GCT CAG A-3´/5´-GAA GAT CTT CTT CTT GAG GG-
3´. Murine SLC and human IgG1-Fc genes were cloned into 
pcDNA3.1 (Invitrogen) vector. NS0 cells were stably transfected 
with pcDNA3.1-SLC-Fc using lipofectamine 2000 (Invitrogen) 
and selected with 0.5 mg/mL geneticin (G418). Stably transfect-
ed clones were tested for SLC-Fc expression by ELISA and che-
motaxis assay. Selected clones were cultured in UltraCulture se-
rum free media (BioWhittaker, Walkersville, MD, USA) supple-
mented with 1% L-glutamine and 1% antibiotics. SLC-Fc pro-
tein was purified using HiTrap Protein G column (GE Health-
care, Piscotaway, NJ, USA). 
ELISA
ELISA plates (Costar, Cambridge, MA, USA) were coated over-
night with anti-SLC antibody (BD Pharmingen, San Diego, CA, 
USA) at 4°C. Wells were blocked with PBS containing 1% bovine 
serum albumin (Sigma Aldrich, St. Louis, MO, USA) for 1 hr at 
room temperature (RT) and incubated with NS0 transfectant 
culture supernatants overnight at 4°C. After washing, plates were 
incubated with biotinylated anti-human IgG1 antibody for 3 hr 
at RT followed by strepavidin-conjugated horseradish peroxi-
dase for 1 hr at RT. Color was developed using o-phenylenedi-
amine dihydrochloride (Sigma Aldrich), and absorbance was 
read at 495 nm with a Multiskan Ascent (Labsystems, Santa Clara, 
CA, USA). 
Chemotaxis assay
Lymphocytes were prepared from peripheral LNs. They were 
gently ground between frosted glass slides, passed over nylon 
mesh (70 µm), and resuspended in RPMI 1640 media contain-
ing 10% fetal bovine serum. Assay was performed in 24-well 
plates with a 5-µm pore polycarbonate Transwell insert (Costar). 
NS0 transfectant culture supernatants or recombinant murine 
SLC (R&D Systems, Minneapolis, MN, USA) was added to the 
lower chamber at the indicated concentration in a volume of 
600 µL and incubated at 37°C for 30 min prior to the addition of 
cells. Then 1 × 10
6 cells in 100 µL medium were added to the 
top chamber and incubated for 4 hr. Cells migrating to the bot-
tom chamber were stained with anti-CD4, anti-CD8, and anti-
B220 antibodies (BD Pharmingen, San Diego, CA, USA); count-
ed; and analyzed by FACSCalibur according to the previous re-
ports. Chemotaxis index was calculated as the fold increase in 
lymphocytes migrating in response to the chemoattractant ver-
sus the media control. Oh SM, et al.  •  SLC and CpG-ODN Inhibits Tumor Growth
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In vivo tumor model
Male C57BL/6 (B6, H-2
b) mice were purchased from the Jack-
son Laboratory (Bar Harbor, ME, USA), bred, and maintained 
in pathogen-free conditions at the animal facility of Seoul Na-
tional University College of Medicine. All animal experiments 
were performed with the approval of the Institutional Animal 
Care and Use Committee of Seoul National University. A total 
of 2 × 10
5 B16F10 tumor cells resuspended in 10 µL PBS were 
inoculated subcutaneously in the shaved left flank area. When 
tumor volume reached approximately 150 µL, intratumoral in-
jection of 3 µg purified murine SLC-Fc and/or 10 µg CpG-ODN 
resuspended in 10 µL pyrogen-free water was administered twice 
a week for 1 or 2 weeks (19). Tumor size was monitored every 2 
days, and tumor volumes were estimated as (width × length ×  
height) × π/6. Tumor-infiltrating cells were analyzed at day 11 
after tumor inoculation. Lymphocytes from the draining LNs 
were prepared by gentle grinding between frosted glass slides 
and passing over nylon mesh (70 µm). Cells from the spleen and 
tumor mass were obtained by chopping and treating with colla-
genase D (100 µg/ea) for 25 min at 37°C and then passing it over 
nylon mesh (70 µm). Isolated cells were stained with murine 
antibodies against CD4, CD8, CD11c, CD86, I-A
b (Y3P), CD25, 
CD62L, and CD44 (BD Pharmingen) (20). 
Statistical analyses
The chemotaxis index and migrated cell numbers were expressed 
as means ± SD. A two-tailed Student’s t-test was used to com-
pare measurements taken from the two samples. For in vivo ex-
periments, differences in tumor volume were analyzed using a 
two-way ANOVA. All P values < 0.05 were deemed to indicate 
statistical significance. The SPSS software (ver. 11.0; SPSS Inc., 
Chicago, IL, USA) was used for all statistical analyses.
 
RESULTS 
Chemotactic activity of SLC-Fc for CD4
+ and CD8
+ T cells 
in vitro
The bioactivity of SLC-Fc was tested by investigating the migra-
tion of T lymphocytes using a chemotaxis assay. Chemotactic 
activity of the lymphocytes was assessed by quantifying lympho-
cytes migrating across 5-µm pore membranes in a Transwell 
with chemotactic stimuli placed in the lower chamber. Respond-
er cells were obtained from the peripheral LNs of B6 mice. After 
4 hr incubation time, the number of migrated cells increased 
> 20 fold compared to the isotype control. The percentage of 
CD4
+ and CD8
+ T cells also increased compared to the original 
responder cells (Fig. 1A). The bioactivity of SLC-Fc fusion pro-
tein with recombinant SLC was also compared using chemo-
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Fig. 1. SLC-Fc is chemotactic for CD4
+ and CD8
+ T cells in vitro. A total of 1 × 10
6 lymphocytes from peripheral LNs of B6 male mice were incubated in the upper chamber of 
the Transwell. After 4 hr incubation, migrated cells in the lower chamber were stained with anti-CD4, anti-CD8, and anti-B220 antibodies and analyzed by FACSCalibur. (A) Flow 
cytometric analysis of migrated cells in the lower chamber with culture media, 300 ng SLC-Fc, or 200 ng recombinant SLC (rSLC). Data shown are representative of two inde-
pendent experiments. (B, C) Chemotaxis assay performed with 0.2 µg recombinant SLC or 3, 0.3, or 0.03 µg purified SLC-Fc in the lower chamber. The chemotaxis index was 
calculated as described in Materials & Methods. Data represent means ± SD, based on three independent determinations using samples in triplicate. *P ≤ 0.05; 
†P ≤ 0.005.
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taxis assay. The chemotactic activity of SLC-Fc was comparable 
to that of recombinant SLC. The result was also dose dependent 
(Fig. 1B, C).
Synergistic inhibition of tumors growth by intratumoral 
injection of SLC-Fc and CpG-ODN
An in vivo melanoma model was established by subcutaneous 
injection of 2 × 10
5 B16F10 melanoma cells into 10- to 12-week-
old B6 male mice. Tumor size was measured every 2 days. To eval-
uate the effect of SLC-Fc on the reduction of established tumors, 
we performed intratumoral injection of 3 µg SLC-Fc two or four 
times when the tumor volume reached approximately 150 µL. 
Compared to the vehicle-treated control, SLC-Fc treatment re-
duced the tumor size in a dose-dependent manner (Fig. 2A). 
  The effect of CpG-ODN was also evaluated by intratumoral 
injection when the tumor volume reached approximately 150 
µL. Tumor growth was inhibited by a single treatment of CpG-
ODN in a dose-dependent manner (Fig. 2B), and treatment with 
10 µg CpG-ODN twice per week for 2 weeks greatly reduced the 
growth of the established tumor (Fig. 2C). 
  Synergistic antitumor effects of SLC-Fc and CpG-ODN were 
evaluated by-intratumoral co-treatment when the tumor vol-
ume reached approximately 150 µL. Tumor growth was inhibit-
ed most efficiently with SLC-Fc/CpG-ODN co-treatment com-
pared to single treatment (Fig. 3). 
Recruitment of T cells and DCs inside the tumor and the 
antitumor activity of SLC-Fc and CpG-ODN
Eleven days after the initiation of intratumoral injections of SLC-
Fc and/or CpG-ODN, infiltrating cells inside the tumor were 
analyzed using a flow cytometer. The percentages of CD4
+ and 
CD8
+ T cells were increased in SLC-Fc-treated (CD4
+ T: 14.7%, 
CD8
+ T: 13.1%), CpG-ODN-treated (CD4
+ T: 10%, CD8
+ T: 15.6%), 
Fig. 2. Intratumoral injection of CpG-ODN induces the rejection of established tumors. 
Ten- to 12-week-old B6 male mice were inoculated subcutaneously with 2 × 10
5 
B16F10 melanoma cells in the shaved left flank. Tumor size was recorded every 2 
days. Intratumoral injection was performed when the tumor volume reached approxi-
mately 150 µL. (A) SLC-Fc treatment (3 µg), two or four times. (B) CpG-ODN treat-
ment (1, 5, or 10 µg) once. (C) CpG-ODN treatment (1, 5, or 10 µg), two times. Data 
represent means ± SD of two independent determinations with n = 6 mice/group. 
*P < 0.05; 
†P < 0.01; 
‡P < 0.001.
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Fig. 3. Synergistic antitumor effect of SLC-Fc and CpG-ODN. Ten- to 12-week-old B6 
male mice were inoculated subcutaneously with 2 × 10
5 B16F10 melanoma cells in 
the shaved left flank. Tumor size was recorded every 2 days. Intratumoral injection 
was performed when the tumor volume reached approximately 150 µL. Data repre-
sent means ± SD of two independent determinations with n = 6 mice/group.Oh SM, et al.  •  SLC and CpG-ODN Inhibits Tumor Growth
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and SLC-Fc/CpG-ODN co-treated (CD4
+ T: 15.2%, CD8
+ T: 11.7%) 
groups compared to the vehicle-treated control group (CD4
+ T: 
0.76%, CD8
+ T: 0.79%). The SLC-Fc-treated group (CD11c
+: 7.7%, 
CD11c
+CD86
+: 16.2%) and the CpG-ODN-treated group (CD11c
+: 
13.5%, CD11c
+CD86
+: 36.3%) showed a greater increase in DC 
population and mature DCs compared to the vehicle-treated 
control group (CD11c
+: 3.35%, CD11c
+CD86
+: 15.6%). Co-treat-
ment of SLC-Fc and CpG-ODN further increased the tumor-in-
filtrating DC population (CD11c
+: 18.2%, CD11c
+CD86
+: 49.2%) 
(Fig. 4A). Expression of MHC class II molecule I-A
b, detected by 
Y3P antibody, on DCs was also increased in SLC-Fc and/or CpG-
ODN treated mice compared to the vehicle-treated control group 
(Fig. 4A). Total numbers of the tumor-infiltrating cells were in-
creased in CpG-ODN- or SLC-Fc- treated mice compared to the 
vehicle-treated control group; co-treatment of SLC-Fc and CpG-
ODN further increased these cells compared to the CpG-ODN- 
or SLC-Fc- treated groups (Fig. 4B). When the phenotypes of the 
subpopulations of tumor-infiltrating cells were further analyzed, 
the synergistic effect of co-treated SLC-Fc and CpG-ODN in in 
vivo tumor growth was explained by the synergistic/additive 
increase of CD4
+ T cells and CD11c
+ DCs in co-treatment group 
compared to the single treatment groups (Fig. 4C). 
 
DISCUSSION 
Most tumor vaccine strategies rely on the availability of well-
characterized tumor antigens or their antigenic peptides. Be-
cause few tumor-specific antigens have been characterized, and 
antigen-specific treatment of tumors is frequently ineffective, 
alternative or supplemental strategies are required. We focused 
on inducing a tumor-specific adaptive immune response inside 
the tumor. For an effective antitumor immune response, we as-
sumed two prerequisites: a chemokine that can recruit lympho-
cytes and APCs, and an adjuvant that can activate APCs. We 
chose SLC, which recruits lymphocytes and DCs into the sec-
ondary lymphoid organ through the CCR7 receptor, and CpG-
ODN, which mimics prokaryotic stimulation. In addition, SLC 
induces angiostatic activity through interaction with another 
receptor, CXCR3, which potentiates an antitumor response. 
  Intratumoral injection of SLC-Fc inhibited tumor growth and 
induced T cell and DC accumulation in the tumor mass. Single 
treatment of CpG-ODN reduced the tumor in a dose-dependent 
manner, and repeated intratumoral injection of CpG-ODN re-
sulted in strong inhibition of the growth of established tumors. 
CpG-ODN does not directly activate T lymphocytes (data not 
shown) but exerts its effect via induction of migration and mat-
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Fig. 4. Recruitment of T cells and DCs inside the tumor. B16F10 melanoma cells (2 × 10
5) were inoculated in the shaved left flank of B6 mice. When the tumor volume reached 
approximately 150 µL, mice were received with PBS, 10 µg CpG-ODN (twice), 3 µg SLC-Fc (twice), or 10 µg CpG-ODN plus 3 µg SLC-Fc (twice). Eleven days after intratumoral 
administration of CpG-ODN and/or SLC-Fc, tumors were removed. Infiltrating cells in the tumor mass were obtained by treatment with collagenase D (100 µg/ea) for 25 min at 
37°C and stained with anti-CD4, anti-CD8, anti-CD11c, anti-CD86, and anti-I-A
b (Y3P) antibodies. (A) Populations of the infiltrating cells in the tumor mass were analyzed by 
flow cytometry. (B) Total numbers of the infiltrating cells in the tumor mass were counted. (C) Each population of the infiltrating cells in the tumor mass was calculated from 
data based on flow cytometry analysis. Data represent means±SD of two independent determinations with n = 4 mice/group.
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uration of DCs inside the tumor mass. Thus, repeated CpG-ODN 
treatment leads to a continuous priming of T cells by activated 
APCs. One caveat for this regimen is that repeated administra-
tion of CpG-ODN was recently reported to alter the structure 
and function of secondary lymphoid organs (21). CpG-ODN 
treatment over 7 days strongly reduced primary humoral im-
mune responses and immunoglobulin class switching. By day 
20 of CpG-ODN administration, mice developed multifocal he-
patic necrosis and hemorrhagic ascites (21). Thus, repeated ap-
plication of CpG-ODN has potential problems as a long-term 
treatment regimen. In this context, synergistic effects of SLC-Fc 
and CpG-ODN shown in this report could reduce the dosage of 
CpG-ODN, reducing the potential harmful side effects of this 
reagent.
  Chemokines have recently been introduced in tumor immu-
notherapy as a means of recruiting effector immune cells (22). 
Among these, CXCL12, CXCL14, CCL16, CCL20, and CCL21 
(SLC) have provided for tumor regression in various treatment 
modalities, including direct injection and induced expression 
in tumor cells (23-26). In addition to the recruitment of inflam-
matory cells, chemokines are involved in lymphoid organogen-
esis. The presence of intratumoral lymphoid structures is corre-
lated with the long-term survival of cancer patients (27); a recent 
report showing that lymphoid-like structures are induced sur-
rounding tumors expressing CCL21 (28) is intriguing. As recruit-
ment of inflammatory cells is not sufficient for full activation of 
tumor-specific T cells, a combination with an activating signal 
would represent an improved strategy. In this context, forced 
expression of CCL21 and LIGHT had a synergistic antitumor ef-
fect (29). Induced expression of LIGHT in the tumor can induce 
substantial infiltration of naïve T cells correlating with an up-
regulation of both chemokine (notably CCL21) production and 
expression of adhesion molecules (30). Thus, the effect of LIGHT 
expression is not immediate but requires the upregulation of 
downstream effector molecules. Thus, co-administration of 
CCL21 and CpG-ODN in this study would act immediately by 
recruiting inflammatory cells and activating them in the tumor 
sites. 
  Antitumor effects of SLC-Fc and CpG-ODN co-treatment con-
tinued until 27 days of tumor inoculation. Very small tumors 
eventually slowly grew out after this time. Thus, the treatment 
schedule for these reagents should be optimized to ensure more 
effective long-term tumor growth inhibition. Moreover, the use 
of additional treatment modalities that use other immunomod-
ulating strategies, such as blocking tumor-induced immune tol-
erance mechanisms, could result in improved tumor immuno-
therapies.
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AUTHOR SUMMARY
Intratumoral Administration of Secondary Lymphoid Chemokine and Unmethylated 
Cytosine-phosphorothioate-guanine Oligodeoxynucleotide Synergistically Inhibits 
Tumor Growth in Vivo
So Mi Oh, Keunhee Oh and Dong-Sup Lee
Appropriate interaction of tumor-specific T cells and mature dendritic cells equipped with tumor antigens is a prerequisite for 
effective T cell immunity against tumors. We mobilized lymphocytes and dendritic cells to tumor sites by intratumoral injection of 
SLC-Fc fusion protein using the B16F10 murine melanoma model. Such treatment showed antitumor effects against the 
melanoma grown in the subcutaneous space. Co-treatment of SLC-Fc and CpG-ODN displayed synergistic antitumor effects, and 
the effects were correlated with the infiltration of T cells and dendritic cells. These results suggest that the combined use of 
chemokines and adjuvant molecules may be a possible strategy in clinical tumor immunotherapy.